RxDoctor Payments Data

Maureen Phillips, MD

Family Medicine · New Berlin, WINPI 1568446110

Payments from drug & device makers

$1,442in general payments, 2019–2025

Across 61 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$218
  • Lilly USA, LLC$154
  • Mallinckrodt Hospital Products Inc.$149
  • Pfizer$141
  • Zimmer Biomet$120
  • Dexcom, Inc.$89
  • plus $571 from 17 others

What the payments were for

  • Food & beverage$1,442100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,442 in reported general payments places this provider in the 90th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$51,167
Medicare patients
152
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$81,141
MyrbetriqMirabegron101$66,596
JardianceEmpagliflozin73$65,479
EliquisApixaban92$55,693
TrulicityDulaglutide31$48,580
MounjaroTirzepatide30$31,731
FarxigaDapagliflozin Propanediol35$25,502
Spiriva HandihalerTiotropium Bromide25$23,243
SymbicortBudesonide/Formoterol Fumarate40$15,677
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$14,475
LinzessLinaclotide19$13,154
Breo ElliptaFluticasone/Vilanterol11$10,788
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$10,206
Fluticasone-SalmeterolFluticasone Propion/Salmeterol50$9,623
XareltoRivaroxaban16$9,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$154$80,31161 claims
Boehringer IngelheimJardiance, Stiolto Respimat$24$79,95499 claims
PfizerEliquis$141$55,69392 claims
AstraZenecaFarxiga, Symbicort$23$41,17975 claims
AbbVieLinzess, Synthroid$59$16,34680 claims
GSKBreo Ellipta, Incruse Ellipta$28$15,84863 claims
Johnson & JohnsonXarelto$13$9,54616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in New Berlin

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →